Skip to main content
Registrieren
Springer Medizin Österreich
SUCHE
MENÜ 1 2 3 4
main-content
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 21-22/2021

26.03.2021 | perspective

New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy

verfasst von: Prof. Dr. Marco Idzko, Sylvia Hartl, Bernd Lamprecht, Matthias Reisinger, Judith Löffler-Ragg, Markus Rauter, Michael Studnicka, Wolfgang Pohl

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Asthma has been recognized as an inflammatory disease, with chronic airway inflammation underlying bronchial hyperresponsiveness and bronchoconstriction [ 1, 2]. Several studies established the presence of increased numbers of inflammatory cells including eosinophils, dendritic cells, type 2 innate lymphoid cells (ILC2), mast cells and lymphocytes in the lung tissue, bronchoalveolar lavage, and sputum from asthmatic patients [ 1‐ 7]. Airway inflammation increases at times of exacerbations and is even present in patients with mild asthma despite a relatively low burden of symptoms [ 8]. …
Vorheriger Artikel New insights and antimicrobial stewardship opportunities in viral pneumonia: five lung ultrasound cases
Nächster Artikel Correction to: Potential association of the prognostic index and survival in patients with p16-positive oropharyngeal squamous cell carcinoma

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Jetzt informieren
Literatur
1.
Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800. PubMed
2.
Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360–72. PubMed
3.
Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM, et al. Eosinophils, T‑lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol. 1991;88(4):661–74. PubMed
4.
Kirby JG, Hargreave FE, Gleich GJ, O’Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis. 1987;136(2):379–83. PubMed
5.
Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992;47(1):25–9. PubMedPubMedCentral
6.
7.
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. PubMed
8.
Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. PubMed
9.
10.
11.
Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev. 2001;4:CD3274.
12.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–6. PubMed
13.
Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880–4. PubMedPubMedCentral
14.
Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995;108(5):1228–34. PubMed
15.
Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157–66. PubMed
16.
17.
Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007;119(4):916–23. PubMed
18.
Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83(4):330–3. PubMedPubMedCentral
19.
Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. PubMedPubMedCentral
20.
Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–6. PubMed
21.
Nathan RA, Thompson PJ, Price D, Fabbri LM, Salvi S, González-Díaz S, et al. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract. 2015;3(5):734–742.e5. PubMed
22.
Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise asthma and link to symptoms and experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. PubMedPubMedCentral
23.
Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66–74. PubMed
24.
Braido F, Brusselle G, Guastalla D, Ingrassia E, Nicolini G, Price D, et al. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional AND longitudinal assessment on asthma control (liaison) study. Respir Res. 2016;17(1):51. PubMedPubMedCentral
25.
O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50(3):1701103. PubMed
26.
Beasley R, Bird G, Harper J, Weatherall M. The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. Eur Respir J. 2018;52(5):1800694. PubMed
27.
Lenney W, Milner AD, Hiller EJ. Continuous and intermittent salbutamol tablet administration in asthmatic children. Br J Dis Chest. 1979;73(3):277–81. PubMed
28.
Shepherd GL, Hetzel MR, Clark TJ. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest. 1981;75(2):215–7. PubMed
29.
Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140(10):802–13. PubMed
30.
Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2020;110(6):S322–8.
31.
Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β‑agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–7. PubMed
32.
Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3 Pt 1):604–10. PubMed
33.
Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79(4):653–9. PubMed
34.
Gavreau G, Jordana M, Watson RM, Cockroft DW, O’Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 1997;156(6):1738–45.
35.
36.
Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–87. PubMed
37.
O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–76. PubMed
38.
O’Byrne P, Fitzgerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. Eur Respir J. 2018;52(62):OA1680.
39.
Buhl R, Kuna P, Peters MJ, Andersson TL, Naya PI, Peterson S, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13:59. PubMedPubMedCentral
40.
Beasley N, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–30. PubMed
41.
Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–28. PubMed
42.
Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison TW, et al. ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. Eur Respir J. 2020;55:1901407. PubMed
43.
Licskai C, Yang CL, Lemiere C, Ducharme FM, Lougheed MD, Radhakrishnan D, et al. Are the 2019 global initiative for asthma (GINA) strategy recommendations applicable to the Canadian context? Can J Respir Crit Care Sleep Med. 2020;4(1):3–6.
44.
O’Byrne P, Bateman ED, FitzGerald JM, Barnes PJ, Zhong N, Alagappan VKT, et al. Efficacy of as-needed budesonide/formoterol for reducing severe exacerbations in adolescents with mild asthma: pooled subgroup analysis of the SYGMA 1 and 2 trials. Am J Respir Crit Care Med. 2020;201:A7191.
Metadaten
Titel
New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy
verfasst von
Prof. Dr. Marco Idzko
Sylvia Hartl
Bernd Lamprecht
Matthias Reisinger
Judith Löffler-Ragg
Markus Rauter
Michael Studnicka
Wolfgang Pohl
Publikationsdatum
26.03.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 21-22/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01830-1

Weitere Artikel der Ausgabe 21-22/2021

Wiener klinische Wochenschrift 21-22/2021 Zur Ausgabe

original article

Multimodal assessment of disease activity in glioblastoma

original article

Expression profiles of miR-196, miR-132, miR-146a, and miR-134 in human colorectal cancer tissues in accordance with their clinical significance

original article

Chemobrachyradiotherapy and consolidation chemotherapy in treatment of locally advanced cervical cancer

original article

Static and dynamic balance impairment and relationship with disease-related factors in patients with chronic obstructive pulmonary disease

MUW researcher of the month

MUW researcher of the month

original article

Potential association of the prognostic index and survival in patients with p16-positive oropharyngeal squamous cell carcinoma

Version: 0.1954.0